Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with alzheimer disease and controls

Journal of Nuclear Medicine

Volumn 53, Issue 6, 2012, Pages 902-907

  Newberg, Andrew B ^a   Arnold, Steven E ^b   Wintering, Nancy ^a   Rovner, Barry W ^a   Alavi, Abass ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer disease; Amyloid imaging; Fluorodeoxyglucose; Positron emission tomography

Indexed keywords

FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; CEREBELLUM; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; INTERMETHOD COMPARISON; MALE; MINI MENTAL STATE EXAMINATION; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANILINE COMPOUNDS; ETHYLENE GLYCOLS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84861855839     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.099606     Document Type: Article

References (38)

1. Ginsberg SD, Schmidt ML, Crino PB, Eberwine JH, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer's disease and related disorders. In: Peters A, Morrison JH, eds. Cerebral Cortex: Neurodegenerative and Age-Related Changes In Structure and Function of Cerebral Cortex. New York, NY: Kluwer Academic/Plenum. 1999:603-654.
2. Selkoe DJ. The origins of Alzheimer disease: A is for amyloid. JAMA. 2000;283:1615-1617. (Pubitemid 30161520)
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944. (Pubitemid 14076461)
4. Tierney MC, Gisher RH, Lewis AJ, et al. The NINCDS-ADRDA Workgroup criteria for the clinical diagnosis of probable Alzheimer's disease: a clinical pathological study of 57 cases. Neurology. 1988;38:359-364. (Pubitemid 18083667)
5. Joachim CL, Morris JH, Selkow DJ. Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases. Ann Neurol. 1988;24:50-56.
6. 18F-deoxyglucose and positron emission tomography. Exp Brain Res. 1982;(suppl 5):187-195.
7. Heiss WD, Kessler J, Szelies B, et al. Positron emission tomography in the differential diagnosis of organic dementias. J Neural Transm Suppl. 1991;33:13-19.
8. Kumar A, Schapiro MB, Grady C, et al. High-resolution PET studies in Alzheimer's disease. Neuropsychopharmacology. 1991;4:35-46.
9. Bonte FJ, Hom J, Tinter R, Weiner MF. Single photon tomography in Alzheimer's disease and the dementias. Semin Nucl Med. 1990;20:342-352.
10. Friedland RP, Budinger TF, Brant-Zawadzki M, et al. The diagnosis of Alzheimer-type dementia: a preliminary comparison of positron emission tomography and proton magnetic resonance. JAMA. 1984;252:2750-2752. (Pubitemid 15200150)
11. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302-316.
12. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120-2127. (Pubitemid 34041597)
13. Patwardhan MB, McCrory DC, Matchar DB, Samsa GP, Rutschmann OT. Alzheimer disease: operating characteristics of PET: a meta-analysis. Radiology. 2004;231:73-80. (Pubitemid 38375412)
14. Selkoe DJ. Imaging Alzheimer's amyloid. Nat Biotechnol. 2000;18:823-824. (Pubitemid 30640902)
15. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356. (Pubitemid 34790756)
16. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740-2754.
17. Ono M, Kung M-P, Hou C, Kung HF. Benzofuran derivatives as Aβ-aggregate-specific imaging agents for Alzheimer's disease. Nucl Med Biol. 2002;29:633-642. (Pubitemid 35266662)
18. Wilson A, Nobrega J, Houle S, et al. Radiosynthesis and evaluation of potential β-amyloid imaging radiotracer for PET. J Labelled Comp Radiopharm. 2003;46:S61-S65.
19. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease: binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24-35.
20. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275-283.
21. 18F]AV-45, a novel amyloid imaging agent: a pilot study. Nucl Med Biol. 2010;37:497-508.
22. 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913-920.
23. Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404-1411.
24. Shin J, Tsui W, Lee S-Y, et al. Resting-state glucose metabolism level is associated with the regional pattern of amyloid pathology in Alzheimer's disease. Inter J Alz Dis. 2011;2011:759780.
25. Langbaum JB, Chen K, Lee W, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage. 2009;45:1107-1116.
26. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci. 1978;25:638-643.
27. Friston KJ, Frackowiak RS. Cerebral function in aging and Alzheimer's disease: the role of PET. Electroencephalogr Clin Neurophysiol Suppl. 1991;42:355-365.
28. Friedland RP, JagustWJ, Huesman RH, et al. Regional cerebral glucose transport and utilization in Alzheimer's disease. Neurol (Tokyo). 1989;39:1427-1434. (Pubitemid 19285995)
29. Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober B. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology. 1988;38:909-912.
30. Ichimiya A, Herholz K, Mielke R, et al. Difference of regional cerebral metabolic pattern between presenile and senile dementia of the Alzheimer type: a factor analytic study. J Neurol Sci. 1994;123:11-17. (Pubitemid 24167421)
31. Mazziotta JC, Frackowiak RSJ, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Semin Nucl Med. 1992;22:233-246.
32. KushnerM, Tobin M, Alavi A, et al. Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG and PET. J Nucl Med. 1987;28:1667-1670.
33. Chase TN, Foster NL, Fedio P, et al. Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Ann Neurol. 1984;15:S170-S174. (Pubitemid 14138680)
34. McGeer EG, Peppard RP, McGeer PL, et al. 18-Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases. Can J Neurol Sci. 1990;17:1-11. (Pubitemid 20101016)
35. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104-1113. (Pubitemid 36988222)
36. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002;159:738-745. (Pubitemid 34465046)
37. Kim EJ, Cho SS, Jeong Y, et al. Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain. 2005;128:1790-1801. (Pubitemid 41373650)
38. Cohen AD, Price JC, Weissfeld LA, et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci. 2009;29:14770-14778.